Managed care issues in the treatment of gastroesophageal reflux disease

American Journal of Managed Care

Volumn 6, Issue 16 SUPPL., 2000, Pages

  DeVault, K R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; UNCLASSIFIED DRUG;

CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DRUG EFFICACY; ESOPHAGITIS; GASTROINTESTINAL REFLUX; HUMAN; MANAGED CARE; PRIORITY JOURNAL; QUALITY OF LIFE;

COST OF ILLNESS; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HUMANS; LIFE STYLE; MANAGED CARE PROGRAMS; OMEPRAZOLE; PROTON PUMPS; QUALITY OF LIFE;

EID: 0033785247     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Quality of life in patients with upper gastrointestinal symptoms: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)
2. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases
3. The impact of gastroesophageal reflux disease on health-related quality of life
4. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastrooesophageal reflux disease
5. Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole
6. A double-blind trial comparing high dose liquid antacid to placebo and cimetidine in improving symptoms and objective parameters in gastroesophageal reflux
7. Pharmacological management of gastrooesophageal reflux disease
8. The medical therapy of reflux oesophagitis
9. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome
10. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology
11. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: A prospective, controlled trial
12. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
13. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group
14. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastrooesophageal reflux disease. The European Rabeprazole Study Group
15. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial
16. Comparison of esomeprazole, a novel PPI, vs omeprazole in GERD patients with erosive esophagitis